In this episode, Jesus Berdeja, MD; Amrita Krishnan, MD, FACP; and Sagar Lonial, MD, FACP, discuss key topics with CELMoD therapy for multiple myeloma, including: 

• Mechanistic differences between CELMoDs and IMiDs
• Emerging data with CELMoDs and their potential therapeutic roles across the disease continuum of multiple myeloma
• The clinical implications of MRD negativity as a surrogate marker of long-term outcomes in clinical trials in multiple myeloma

Presenters:

Jesus Berdeja, MD
Director of Myeloma Research
Greco-Hainsworth Centers for Research
Tennessee Oncology
Nashville, Tennessee

Amrita Krishnan, MD, FACP
Director, Judy and Bernard Briskin Center for Myeloma
Executive Director of Hematology
City of Hope Orange County
Professor of Hematology/HCT
City of Hope Cancer Center
Irvine, California

Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University
Atlanta, Georgia

Content based on an online CME program supported by an independent educational grant from Bristol Myers Squibb.

Link to full program: 
https://bit.ly/3IwbslQ